Augustine Asset Management Inc. Raises Holdings in Dr. Reddy’s Laboratories Limited (NYSE:RDY)

Augustine Asset Management Inc. grew its stake in shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 392.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 249,744 shares of the company’s stock after acquiring an additional 199,044 shares during the quarter. Dr. Reddy’s Laboratories comprises approximately 1.0% of Augustine Asset Management Inc.’s investment portfolio, making the stock its 18th largest holding. Augustine Asset Management Inc.’s holdings in Dr. Reddy’s Laboratories were worth $3,943,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Robeco Institutional Asset Management B.V. increased its stake in Dr. Reddy’s Laboratories by 453.8% during the 4th quarter. Robeco Institutional Asset Management B.V. now owns 11,438,908 shares of the company’s stock valued at $180,620,000 after purchasing an additional 9,373,412 shares in the last quarter. State Street Corp grew its holdings in shares of Dr. Reddy’s Laboratories by 1.9% during the third quarter. State Street Corp now owns 909,905 shares of the company’s stock valued at $72,292,000 after buying an additional 16,641 shares during the last quarter. Fisher Asset Management LLC increased its position in shares of Dr. Reddy’s Laboratories by 59.4% in the 3rd quarter. Fisher Asset Management LLC now owns 491,303 shares of the company’s stock valued at $39,034,000 after acquiring an additional 183,146 shares during the period. BNP Paribas Financial Markets raised its stake in Dr. Reddy’s Laboratories by 30.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 409,440 shares of the company’s stock worth $32,530,000 after acquiring an additional 96,339 shares during the last quarter. Finally, Artemis Investment Management LLP lifted its position in Dr. Reddy’s Laboratories by 398.3% during the 4th quarter. Artemis Investment Management LLP now owns 295,530 shares of the company’s stock worth $4,666,000 after acquiring an additional 236,224 shares during the period. 3.85% of the stock is owned by hedge funds and other institutional investors.

Dr. Reddy’s Laboratories Price Performance

NYSE:RDY opened at $13.82 on Wednesday. The firm’s fifty day moving average is $14.76 and its two-hundred day moving average is $15.34. The firm has a market cap of $11.53 billion, a price-to-earnings ratio of 22.00 and a beta of 0.50. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.38 and a current ratio of 1.92. Dr. Reddy’s Laboratories Limited has a one year low of $13.36 and a one year high of $16.89.

Dr. Reddy’s Laboratories (NYSE:RDY) last issued its earnings results on Thursday, January 23rd. The company reported $0.20 EPS for the quarter, topping analysts’ consensus estimates of $0.19 by $0.01. Dr. Reddy’s Laboratories had a return on equity of 17.87% and a net margin of 17.25%. Research analysts expect that Dr. Reddy’s Laboratories Limited will post 0.8 EPS for the current year.

Analyst Ratings Changes

RDY has been the topic of a number of research reports. StockNews.com lowered Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a report on Friday, December 6th. Nomura downgraded shares of Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a report on Thursday, December 19th. Finally, Barclays reduced their price target on shares of Dr. Reddy’s Laboratories from $17.40 to $17.00 and set an “overweight” rating for the company in a research report on Wednesday, November 6th.

Dr. Reddy’s Laboratories Company Profile

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.